Pfizer Doubles Down on MRNA Tech With Three Deals

Pfizer Inc has signed three deals to broaden the use of the messenger RNA technology (mRNA) that its COVID-19 vaccine was based on, including a pact worth as much as $1.35 billion with gene-editing specialist Beam Therapeutics.

Pfizer will also collaborate with Codex DNA Inc for an undisclosed sum to leverage the biotech’s proprietary technology, which could enable more efficient development of mRNA-based vaccines, therapeutics and other biopharma products. Its collaboration with private biotech Acuitas Therapeutics will focus on the use of the Vancouver-based company’s lipid nanoparticle (LNP) technology for developing up to ten vaccines or therapeutics. The financial details of the deal were not disclosed

https://money.usnews.com/investing/news/articles/2022-01-10/pfizer-joins-beam-therapeutics-to-develop-rare-disease-therapies

Looks like they’re planning on changing mankind (or what’s left of it) for the foreseeable future

Tess

Leave a Comment


This site uses Akismet to reduce spam. Learn how your comment data is processed.